CXCL8 and lung cancer: Numasaki et al. also demonstrated IL-17's net angiogenic effects on human nonsmall cell lung cancer (NSCLC) cells in immune-compromised mice via CXCL-8 (IL-8) production and its actions on its receptor (CXCR-2) on endothelial cells via selective production of the following angiogenic cytokines: CXCL-1, CXCL-5, CXCL-6, and CXCL-8 [71].